The FDA has granted a breakthrough therapy designation to the combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after at least one prior systemic therapy.
Coping with emotional and physical pain years after a spouse's death from cancer leads to more questions about his treatment.
In this week’s episode of “CURE® Talks Cancer,” we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.
We are always faced with choices on this cancer journey. Even if you end up making a wrong turn, there is always a way to get back on track.
A lunch out with friends may be more therapeutic than you think.
Take a look at the top five CURE stories of July 2018 in this video.
How just another day at work triggered thoughts of having cancer as a child.
If you can't save yourself, try focusing on the family pet, says one cancer survivor.
You are one person before the diagnosis comes, you are another person during the journey and you are different person when remission is gained. That is not to say that certain pieces of you don't remain, but I feel it nearly impossible to go through this journey unchanged.
With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.
The Food and Drug Administration (FDA) has approved Azedra (iobenguane I-131) for adult and pediatric patients aged 12 years or older with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.
The speakers noted that certain well-known cancer centers are highly sought by organizations planning trials, due to their success at enrolling participants. That breeds competition among the hosts of trials to work with those centers and enroll their patients, which is detrimental to the pace of research overall.
I had a revelation while dress shopping. What caused my change from carefree to self-conscious regarding my lopsidedness?
After a cancer diagnosis, some people choose to look at their lives as they once were. Instead of moving forward, they become stuck in the past. Learn how this survivor found a valuable cancer lesson while cutting the grass.
Combating cancer can leave us drained.
Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.
Getting a job while having health issues can be a problem, but don't just take my word for it.
When dealing with cancer, it's important to know your limits and be OK with them, to focus on the good.
Vassiliki A. Papadimitrakopoulou, M.D., honored at the 19th Annual International Lung Cancer Congress.
They say when you begin to help others, you reach a deeper state of healing.
Sometimes life throws you the curveball of cancer.
Researchers are on the hunt for a better biomarker in ovarian cancer that could detect the disease in earlier stages.
The increase in health insurance deductibles has affected health care for many cancer patients. These changes contribute to unnecessary stress in the lives of some affected by breast cancer. Read one survivor's viewpoint.
We as cancer patients need to be involved in our own medical care and to advocate for ourselves and for each other.
Not just an anti-drug slogan, it's a phrase that describes how cancer empowered me to make the best use of my time.
Dr. Inga Hofman Zhang from the University of Wisconsin School of Medicine provides an update on treating MDS in children.
Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship between MDS and AML and discusses new and novel treatments for both diseases.
Dr. Antonio Risitano, a hematologist from the Univeristy of Naples, discusses the most current thinking on PNH and its treatment. Questions answered include:
Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis.
